BioLine RX LtdNASDAQ:BLRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.5900
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.5852/ 1
- Ask / Lots0.6050/ 2
- Open / Previous Close0.6196 / 0.5900
- Day Range
- 52 Week Range
- Volume422,832
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BLRX |
|---|---|---|
| 09:32 ET | 12507 | 0.6136 |
| 09:41 ET | 1297 | 0.6136 |
| 09:50 ET | 200 | 0.6162 |
| 09:52 ET | 65380 | 0.5953 |
| 09:54 ET | 1400 | 0.595199 |
| 09:56 ET | 250 | 0.599499 |
| 09:57 ET | 7750 | 0.5907 |
| 09:59 ET | 6760 | 0.59 |
| 10:01 ET | 11284 | 0.59 |
| 10:03 ET | 1626 | 0.59 |
| 10:06 ET | 2250 | 0.5901 |
| 10:10 ET | 500 | 0.5993 |
| 10:12 ET | 800 | 0.5901 |
| 10:14 ET | 500 | 0.59 |
| 10:15 ET | 2825 | 0.5897 |
| 10:17 ET | 8360 | 0.5898 |
| 10:19 ET | 500 | 0.5851 |
| 10:21 ET | 9300 | 0.5851 |
| 10:24 ET | 7700 | 0.5898 |
| 10:26 ET | 9200 | 0.5898 |
| 10:28 ET | 2150 | 0.5896 |
| 10:32 ET | 9667 | 0.585 |
| 10:33 ET | 500 | 0.58501 |
| 10:35 ET | 4617 | 0.5851 |
| 10:37 ET | 18060 | 0.5851 |
| 10:39 ET | 200 | 0.5896 |
| 10:42 ET | 500 | 0.585145 |
| 10:44 ET | 15836 | 0.58735 |
| 10:46 ET | 1400 | 0.58558 |
| 10:48 ET | 4167 | 0.5896 |
| 10:50 ET | 1000 | 0.59 |
| 10:51 ET | 2999 | 0.5926 |
| 10:57 ET | 100 | 0.599499 |
| 11:00 ET | 125 | 0.5996 |
| 11:04 ET | 400 | 0.5928 |
| 11:08 ET | 917 | 0.5996 |
| 11:09 ET | 3287 | 0.5861 |
| 11:13 ET | 5774 | 0.6 |
| 11:15 ET | 700 | 0.5931 |
| 11:18 ET | 200 | 0.593 |
| 11:22 ET | 400 | 0.586101 |
| 11:26 ET | 3300 | 0.5871 |
| 11:29 ET | 333 | 0.6 |
| 11:42 ET | 35868 | 0.586 |
| 11:51 ET | 400 | 0.5999 |
| 11:54 ET | 21900 | 0.5851 |
| 12:03 ET | 55022 | 0.5901 |
| 12:05 ET | 100 | 0.5901 |
| 12:12 ET | 500 | 0.597 |
| 12:16 ET | 100 | 0.5901 |
| 12:18 ET | 100 | 0.5901 |
| 12:20 ET | 100 | 0.59011 |
| 12:25 ET | 4600 | 0.5902 |
| 12:45 ET | 100 | 0.596 |
| 12:50 ET | 11250 | 0.59 |
| 12:56 ET | 2000 | 0.59 |
| 12:57 ET | 3100 | 0.590201 |
| 01:06 ET | 1750 | 0.5951 |
| 01:08 ET | 5700 | 0.5998 |
| 01:28 ET | 943 | 0.5998 |
| 01:32 ET | 100 | 0.5901 |
| 01:39 ET | 2150 | 0.590301 |
| 01:44 ET | 500 | 0.595051 |
| 01:46 ET | 100 | 0.5902 |
| 01:48 ET | 200 | 0.599799 |
| 01:53 ET | 500 | 0.5902 |
| 01:57 ET | 100 | 0.5901 |
| 02:09 ET | 100 | 0.5911 |
| 02:11 ET | 500 | 0.595281 |
| 02:13 ET | 100 | 0.596 |
| 02:18 ET | 518 | 0.5911 |
| 02:20 ET | 500 | 0.5997 |
| 02:27 ET | 2507 | 0.5911 |
| 02:31 ET | 100 | 0.5911 |
| 02:42 ET | 100 | 0.5911 |
| 02:47 ET | 1000 | 0.5997 |
| 02:49 ET | 100 | 0.5911 |
| 03:03 ET | 100 | 0.5912 |
| 03:12 ET | 400 | 0.5998 |
| 03:14 ET | 100 | 0.5913 |
| 03:23 ET | 1433 | 0.5997 |
| 03:27 ET | 10210 | 0.5998 |
| 03:32 ET | 1514 | 0.5915 |
| 03:34 ET | 3700 | 0.5912 |
| 03:36 ET | 1350 | 0.591 |
| 03:39 ET | 2100 | 0.591 |
| 03:43 ET | 100 | 0.591 |
| 03:45 ET | 100 | 0.591 |
| 03:48 ET | 100 | 0.591 |
| 03:50 ET | 743 | 0.591 |
| 03:52 ET | 6338 | 0.5947 |
| 03:54 ET | 2000 | 0.5924 |
| 03:56 ET | 100 | 0.59 |
| 03:57 ET | 200 | 0.59 |
| 03:59 ET | 200 | 0.59 |
Jun 3, 2024
DJ BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co., from 12:45PM ET on Monday Jun 03, 2024 by Dow Jones
12:45PM ET on Monday Jun 03, 2024 by Dow Jones
May 30, 2024
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD), from 7:00AM ET on Thursday May 30, 2024 by Dow Jones
7:00AM ET on Thursday May 30, 2024 by Dow Jones
May 29, 2024
DJ BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co., from 10:34AM ET on Wednesday May 29, 2024 by Dow Jones
10:34AM ET on Wednesday May 29, 2024 by Dow Jones
May 28, 2024
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates, from 7:00AM ET on Tuesday May 28, 2024 by Dow Jones
7:00AM ET on Tuesday May 28, 2024 by Dow JonesPress Release: BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates, from 7:00AM ET on Tuesday May 28, 2024 by Dow Jones
7:00AM ET on Tuesday May 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioLine RX Ltd | 52.7M | -0.8x | --- |
Dyadic International Inc | 51.5M | -6.6x | --- |
LAVA Therapeutics NV | 51.3M | -1.8x | --- |
Cue Biopharma Inc | 65.7M | -1.2x | --- |
Kronos Bio Inc | 60.7M | -0.5x | --- |
Kezar Life Sciences Inc | 47.7M | -0.5x | --- |
Company Information
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Contact Information
- Headquarters
- Modi'in Technology Park 2 HaMa'ayan StreetMODIIN, Israel 7177871
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Aharon Schwartz
- Chief Executive Officer
- Philip Serlin
- Chief Financial Officer
- Mali Zeevi
- Vice President - Development
- Ella Sorani
- Vice President-Clinical & Medical Affairs
- Abi Vainstein-Haras
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $52.7M |
|---|---|
Revenue (TTM) | $11.7M |
Shares Outstanding | 79.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.52 |
EPS | $-0.76 |
Book Value | $0.18 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | 4.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -391.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
